Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21474611 | 0.90 | LMNA (0.36) | MAPTALDH1A1LMNAKCNK3AVPR2 | |
| SCHEMBL20622238 | 0.80 | NOTUM (0.41) | MAPTALDH1A1STING1L3MBTL1LMNA | |
| SCHEMBL21471605 | 0.80 | SCD (0.31) | ALDH1A1L3MBTL1KCNK3KDM4E | |
| SCHEMBL20622251 | 0.78 | L3MBTL1 (0.45) | MAPTALDH1A1ARL3MBTL1LMNA | |
| SCHEMBL21472051 | 0.76 | AR (0.40) | MAPTALDH1A1ARSTING1L3MBTL1 | |
| SCHEMBL21471613 | 0.76 | NOTUM (0.32) | ALDH1A1L3MBTL1LMNAKDM4EHTT | |
| SCHEMBL21478310 | 0.76 | STING1 (0.36) | MAPTALDH1A1STING1L3MBTL1LMNA | |
| SCHEMBL21472043 | 0.75 | STING1 (0.36) | MAPTALDH1A1STING1L3MBTL1LMNA | |
| SCHEMBL20620169 | 0.74 | HSD11B1 (0.40) | MAPTALDH1A1STING1L3MBTL1LMNA | |
| SCHEMBL20620103 | 0.72 | AVPR2 (0.43) | MAPTALDH1A1STING1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975094-B2 | Heterocyclic compounds as RSV inhibitors | SIRT1, FURIN, SIRT5 | MAPT 3526/4885ALDH1A1 701/4885AR 4319/4885 |
| US-20190315766-A1 | HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS | SIRT1, FURIN, SIRT5 | MAPT 3526/4885ALDH1A1 701/4885AR 4319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.